E-cigarettes may be more effective in helping pregnant smokers quit

May.17.2022
E-cigarettes may be more effective in helping pregnant smokers quit
Pregnant smokers using e-cigarettes are more likely to quit smoking compared to nicotine patch users, according to a study.

Research shows that pregnant smokers are more likely to quit smoking using electronic cigarettes after four weeks than nicotine patches.

 

Researchers have discovered that electronic cigarettes may be equally safe for pregnant women trying to quit smoking as nicotine patches, and may even be a more effective tool.

 

Smoking during pregnancy increases the risk of adverse outcomes such as preterm birth, miscarriage, and low birth weight. However, quitting this habit can be a challenging process.

 

Dr. Francesca Pesola from Queen Mary University of London, the author of this new study, stated that "many pregnant smokers find it difficult to quit smoking using current cessation aids (including nicotine patches) and continue smoking throughout their pregnancy.

 

Although it has been discovered that electronic cigarettes are more effective than nicotine patches in helping people quit smoking, Pesola points out that despite the increasing use of electronic cigarettes by pregnant women, research on their effectiveness or safety is scarce.

 

After attempting to quit smoking for four weeks, 15.4% of individuals who reported using e-cigarettes said that they no longer smoke, compared to only 8.6% of those using nicotine patches.

 

Smoking during pregnancy increases the risk of negative outcomes, including premature birth, miscarriage, and low birth weight for the infant. However, quitting this habit can be a challenging process.

 

Although electronic cigarettes have been shown to be more effective than nicotine patches in helping people quit smoking, Pesola points out that despite an increase in the use of e-cigarettes among pregnant women, there is little research on their effectiveness or safety.

 

Researchers led by Pesola reported in the journal Nature Medicine that they randomly assigned 569 pregnant smokers to use e-cigarettes and 571 pregnant women to use nicotine patches – a nicotine replacement therapy that can already be prescribed during pregnancy. The participants were an average of 15.7 weeks pregnant and smoked 10 cigarettes per day.

 

Only 40% of participants received an electronic cigarette and 23% received a patch, both of which were used for at least four weeks. However, during the study period, those who received electronic cigarettes had higher usage rates and longer usage times.

 

Excluding participants who self-reported not smoking but using nicotine products other than those assigned to them, such as those using nicotine patches along with e-cigarettes, the research team found that those who received e-cigarettes appeared to do better in terms of smoking cessation.

 

After attempting to quit smoking for four weeks, 15.4% of individuals self-reported that they had not smoked, compared to only 8.6% of those who were given patches. At the end of their pregnancies, 19.8% of the e-cigarette group self-reported that they had quit smoking, while only 9.7% of the patch group had done so.

 

Only a small number of participants provided saliva samples to confirm smoking cessation at the end of pregnancy, but once those who used unassigned products were excluded, the research group found that the quit rates among the electronic cigarette group were higher.

 

Additionally, the research team found that the incidence of adverse events was similar between individuals who were given cigarettes and those who were given patches. More importantly, although the average birth weight of infants was similar, low birth weight was more common in the patch group.

 

However, this study has limitations, including low compliance and the use of electronic cigarettes that differ from modern devices.

 

The author further stated that due to the potential risks of nicotine during pregnancy, it is best for pregnant women to quit smoking without using nicotine-containing products.

 

Pesola stated, "We only recommend nicotine use for smokers who wish to quit traditional cigarettes.

 

However, she added, "The risks posed to mothers or infants by using electronic cigarettes are no greater than those posed by nicotine patches. Both are better choices than continuing to smoke throughout the entire course of pregnancy.

 

Source: The Guardian

 

E-cigarettes are equally safe as nicotine patches for pregnant women who smoke and are attempting to quit, according to a report in The Guardian on May 16, 2022.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Gallup Tracks Nicotine Pouch Use for the First Time: 11% of U.S. Adults Smoke, 9% Vape and 4% Use Nicotine Pouches
Gallup Tracks Nicotine Pouch Use for the First Time: 11% of U.S. Adults Smoke, 9% Vape and 4% Use Nicotine Pouches
Gallup’s 2026 Consumption Habits survey tracked nicotine pouch use for the first time. The survey found that 11% of U.S. adults reported smoking cigarettes in the past week, 9% reported vaping, and 4% reported using nicotine pouches. Cigarette smoking remained near Gallup’s long-term low, while adult vaping rates stayed relatively stable in recent years.
Market
Aug.25 by 2Firsts Perspectives
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28